During the last session, Gilead Sciences, Inc. (NASDAQ:GILD)’s traded shares were 6.58 million, with the beta value of the company hitting 0.21. At the end of the trading day, the stock’s price was $69.58, reflecting an intraday gain of 0.04% or $0.03. The 52-week high for the GILD share is $87.86, that puts it down -26.27 from that peak though still a striking 0.27% gain since the share price plummeted to a 52-week low of $69.39. The company’s market capitalization is $86.76B, and the average intraday trading volume over the past 10 days was 6.3 million shares, and the average trade volume was 7.52 million shares over the past three months.
Gilead Sciences, Inc. (NASDAQ:GILD) trade information
Gilead Sciences, Inc. (GILD) registered a 0.04% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.04% in intraday trading to $69.58, hitting a weekly high. The stock’s 5-day price performance is -5.01%, and it has moved by -4.20% in 30 days. Based on these gigs, the overall price performance for the year is -15.27%. The short interest in Gilead Sciences, Inc. (NASDAQ:GILD) is 19.25 million shares and it means that shorts have 2.6 day(s) to cover.
Gilead Sciences, Inc. (GILD) estimates and forecasts
Statistics show that Gilead Sciences, Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Gilead Sciences, Inc. (GILD) shares have gone down -6.90% during the last six months, with a year-to-date growth rate less than the industry average at 5.21% against 13.50. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 15.30% this quarter and then jump 27.60% in the quarter after that. In the rating firms’ projections, revenue will increase 1.40% compared to the previous financial year.
Revenue for the current quarter is expected to be $6.36 billion as predicted by 21 analyst(s). Meanwhile, a consensus of 19 analyst(s) estimates revenue growth to $6.78 billion by the end of Jun 2024. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $6.35 billion and $6.6 billion respectively. In this case, analysts expect current quarter sales to grow by 0.20% and then jump by 2.70% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 1.55%. While earnings are projected to return 5.70% in 2024, the next five years will return 5.12% per annum.
GILD Dividends
Gilead Sciences, Inc. is due to release its next quarterly earnings between April 25 and April 29. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance. Investors should also take the other fundamental and operational aspects into account before investing in the stock. The forward dividend ratio for Gilead Sciences, Inc. is 3.02, with the dividend yield indicating at 4.34 percent, continuing the trend of increasing dividends in recent years.
Gilead Sciences, Inc. (NASDAQ:GILD)’s Major holders
Gilead Sciences, Inc. insiders own 0.09% of total outstanding shares while institutional holders control 88.37%, with the float percentage being 88.45%. Blackrock Inc. is the largest shareholder of the company, while 2,400 institutions own stock in it. As of Jun 29, 2023, the company held over 126.19 million shares (or 10.13% of all shares), a total value of $9.73 billion in shares.
The next largest institutional holding, with 113.37 million shares, is of Vanguard Group Inc’s that is approximately 9.10% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $8.74 billion.
Also, the Mutual Funds coming in first place with the largest holdings of Gilead Sciences, Inc. (GILD) shares are Vanguard Total Stock Market Index Fund and Income Fund of America Inc. Data provided on Jun 29, 2023 indicates that Vanguard Total Stock Market Index Fund owns about 38.97 million shares. This amounts to just over 3.13 percent of the company’s overall shares, with a $3.0 billion market value. The same data shows that the other fund manager holds slightly less at 34.44 million, or about 2.76% of the stock, which is worth about $2.58 billion.
